What You Need To Know Ahead of Quest Diagnostics' Earnings Release

Company Overview - Quest Diagnostics Incorporated (DGX) has a market cap of $19.3 billion and is a leading provider of diagnostic testing and information services, offering a range of clinical testing to healthcare providers and patients both in the U.S. and internationally [1] Financial Performance - Analysts expect DGX to report an adjusted EPS of $2.36 for fiscal Q4 2025, reflecting a 5.8% increase from $2.23 in the same quarter last year [2] - For fiscal 2025, the forecasted adjusted EPS is $9.79, which represents a 9.6% increase from $8.93 in fiscal 2024 [3] - In Q3 2025, Quest Diagnostics reported adjusted EPS of $2.60 and revenue of $2.82 billion, with a year-over-year revenue growth of 13.1% and adjusted EPS growth of 13% [5] Stock Performance - Over the past 52 weeks, shares of Quest Diagnostics have increased by 15.1%, which is below the S&P 500 Index's rise of 16.9% but above the State Street Health Care Select Sector SPDR ETF's gain of 13% [4] - Following the Q3 2025 results announcement, the stock fell over 3% despite beating expectations [5] Analyst Ratings - The consensus rating for DGX stock is "Moderate Buy," with 8 out of 18 analysts recommending a "Strong Buy" and 10 giving a "Hold" rating [6] - The average analyst price target for Quest Diagnostics is $199.47, indicating a potential upside of 14.8% from current levels [6]